Cohort Follow-up Studies: Cardiovascular Disease (CVD)
Latavia M. Walston
Strayer University, Epidemiology
What Causes of CVD
Scientist and related health- care providers often use study modules from an epidemiological position to probe unanticipated devices associated to infection, and they come up with solutions to target key factors for therapy and possible prevention. Many modules make this probable for distinguishing basic procedures, risks and outcomes. Cohort follow-up studies cover a specific area of study that labels a subject matter when the outcome of the disease is not visible. Then the study compares the ...view middle of the document...
Key causes of CVD through cohort study designs recognize numerous risk factors that add to CVD. In addition to age, other contributing factors include diet, hypertension, obesity, physical activity, smoking, gender, and family history. Research also suggest that environmental issues are risk factors such as air pollution, certain chemical contact, metals, and medications can cause or worsen preexisting conditions of CVD, (Schettler, 2005). Various cohort studies conducted by researchers emphasized the same risks factors from CVD. After identifying the personal and environmental causes of CVD, finding a suitable solution on how to address the major factors requires further investigation of key strategies including current medications used to address Cardiovascular Disease. In addition, researches and health care officials must draw their attention on the focus of improving cardiovascular health through the treatment of risk factors, prevention, and detection. This strategy depends on a constant investment of all available intervention approaches. Policy and environmental changes designed to prevent risk factors promise quality care for many that suffer with CVD. In addition to policy and environmental changes includes community outreach and education to maintain individual efforts for prevention or control of the major causes.
These strategies are instrumental in addition to medications currently used. Pills containing aspirin, multiple blood pressure drugs, and a drug that reduces levels of fat have proven safe, risk reductions, and improved medication adherence in the prevention of cardiovascular disease. ACE inhibitors are a type of medication that dilates widens arteries to lower blood pressure and make it easier for the heart to pump blood. They also block some of the harmful actions of the endocrine system that may occur during heart failure. Individual medications in the combination of pills are even now recommended for CVD prevention. As a result, current information on the movement of drugs within the body, have an impact on risks factors, and tolerability. This should be sufficient evidence to persuade regulators and clinicians to use a fixed-dose combination pills in high-risk individuals, such as in secondary prevention. Long-term use of these medicines, in such form or otherwise, is expected to reduce the risk of CVD by at least 50–60% in specific groups, ("European Heart Journal," 2014).
Questions posed to DC Health Department
Health organizations all over the U.S. play a major role in monitoring prevention of cardiovascular disease. For example, The Department of Health in DC, The Cardiovascular Health Program executes State-level actions to prevent and control heart disease, diabetes, obesity and other related risk factors. Through multi-sector partnerships, the program aims to increase linkages between clinical care and community resources that support chronic disease self-management. ...